AstraZeneca’s Truqap Demonstrates Phase 3 Success in Prostate Cancer
AstraZeneca’s Truqap (capivasertib) has achieved a significant milestone in the treatment of prostate cancer. Results from the CAPItello-281 Phase III
Read moreAstraZeneca’s Truqap (capivasertib) has achieved a significant milestone in the treatment of prostate cancer. Results from the CAPItello-281 Phase III
Read moreInsitro, a leading AI-driven drug discovery and development company, has entered into three strategic agreements with Eli Lilly and Company
Read moreAbbVie has reported positive topline results from its pivotal Phase 3 TEMPO-1 trial evaluating tavapadon as a monotherapy for early-stage
Read moreThe leading global biotechnology company advancing protein-based vaccines, Novavax, announced that the European Commission has granted Marketing Authorisation for the
Read moreAOP Orphan Pharmaceuticals GmbH (AOP Health), in collaboration with Leukos Biotech, has reached a significant milestone in cancer therapy. The
Read moreIn a landmark approval, the U.S. Food and Drug Administration (FDA) has cleared AstraZeneca’s FluMist, the only influenza vaccine that
Read moreAccelerating Immunoassay Development With Automated Storage, Filling and Labeling – Case Study An HTI Automation & Mabtech Case Study The
Read moreIn a groundbreaking leap, researchers have engineered microscopic magnetic robots that could transform the treatment of deadly brain bleeds caused
Read moreGroundbreaking Research Highlights ipRGCs as Promising Biomarkers for Neurodegenerative Diseases A Striatech .pdf Case Study OptoDrum plays a key role
Read moreGSK has announced promising headline results from its Phase III clinical trial, MATINEE, which evaluated the efficacy of Nucala (mepolizumab)
Read more